Deferoxamine Versus Combined Therapy for Chelating Liver, Spleen and Bone Marrow Iron in β-Thalassemic Patients: A Quantitative Magnetic Resonance Imaging Study

REFERENCES

• Weatherall DJ, Clegg JB, Na-Nakorn S, Wasi P. The pattern of disordered haemoglobin synthesis in homozygous and heterozygous β-thalassaemia. Br J Haematol. 1969;16(3):251–267.
   PubMed Web of Science ®Google Scholar
• Siegelman ES, Mitchell DG, Rubin R, Parenchymal versus reticuloendothelial iron overload in the liver: distinction with MR imaging. Radiology. 1991;179(3):361–366.
   PubMedGoogle Scholar
• Yoon DY, Choi BI, Han JK, Han MC, Park MO, Suh SJ. MR findings of secondary hemochromatosis: transfusional vs erythropoietic. J Comput Assist Tomogr. 1994;1(3):416–419.
   Google Scholar
• Gandon Y, Guyader D, Heautot JF, Hemochromatosis: diagnosis and quantification of liver iron with gradient echo MR imaging. Radiology. 1994;193(2):533–538.
   PubMed Web of Science ®Google Scholar
• Gandon Y, Olivie D, Guyader D, Non-invasive assessment of hepatic iron stores by MRI. Lancet. 2004; 363(9406):357–362.
   PubMed Web of Science ®Google Scholar
• Papakonstantinou OG, Maris TG, Kostaridou V, Assessment of liver iron overload by T2-quantitative magnetic resonance imaging: correlation of T2-QMRI measurements with serum ferritin concentration and histologic grading of siderosis. Magn Reson Imaging. 1995;13(7):967–977.
   PubMed Web of Science ®Google Scholar
• Fenzi A, Bortolazzi M, Marzola P. Comparison between signal-to-noise ratio, liver-to-muscle ratio, and 1/T2 for the noninvasive assessment of liver iron content by MRI. J Magn Reson Imaging. 2003;17(5):589–592.
   PubMed Web of Science ®Google Scholar
• Argyropoulou MI, Metafratzi Z, Kiortsis DN, Bitsis S, Tsatsoulis A, Efremidis S. T2 relaxation rate as an index of pituitary iron overload in patients with β-thalassemia major. Am J Roentgenol. 2000;175(6):1567–1569.
   PubMed Web of Science ®Google Scholar
• Midiri M, Lo Casto A, Sparacia G, MR imaging of pancreatic changes in patients with transfusion-dependent β-thalassemia major. Am J Roentgenol. 1999;173(1):187–192.
   PubMed Web of Science ®Google Scholar
• Drakonaki E, Papakonstantinou O, Maris T, Vasiliadou A, Papadakis A, Gourtsoyiannis N. Adrenal glands in β-thalassemia major: magnetic resonance (MR) imaging features and correlation with iron stores. Eur Radiol. 2005;15(12):2462–2468.
   PubMed Web of Science ®Google Scholar
• Papakonstantinou O, Maris TG, Kostaridou S, Ladis V, Vasiliadou A, Gourtsoyiannis NC. Abdominal lymphadenopathy in β-thalassemia: MRI features and correlation with liver iron overload and posttransfusion chronic hepatitis C. Am J Roentgenol. 2005;185(1):219–224.
   PubMed Web of Science ®Google Scholar
• Kolnagou A, Economides Ch, Eracleous E, Kontoghiorghes GJ. Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols. Hemoglobin. 2008;32(1–2):41–47.
   PubMed Web of Science ®Google Scholar
• Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in β-thalassaemia. Lancet. 2002;360(9332):516–520.
   PubMed Web of Science ®Google Scholar
• Glickstein H, El RB, Shvartsman M, Cabantchik ZI. Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells. Blood. 2005;106(9):3242–3250.
   PubMed Web of Science ®Google Scholar
• Link G, Konijn AM, Breuer W, Cabantchik ZI, Hershko C. Exploring the “iron shuttle” hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture. J Lab Clin Med. 2001;138(2):130–138.
   PubMed Web of Science ®Google Scholar
• Ooi GC, Khong PL, Chan GC, Magnetic resonance screening of iron status in transfusion-dependent β-thalassaemia patients. Br J Haematol. 2004;124(3):385–390.
   PubMed Web of Science ®Google Scholar
• Jensen PD. Evaluation of iron overload. Br J Haematol. 2004;124(6):697–711.
   PubMed Web of Science ®Google Scholar
• Mourad FH, Hoffbrand AV, Sheikh-Taha M, Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. Br J Haematol. 2003;121(1):187–189.
   PubMed Web of Science ®Google Scholar
• Daar S, Pathare AV. Combined therapy with desferrioxamine and deferiprone in β thalassemia major patients with transfusional iron overload. Ann Hematol. 2006;85(5):315–319.
   PubMed Web of Science ®Google Scholar
• Kattamis A, Ladis V, Berdousi H, Iron chelation treatment with combined therapy with deferiprone and deferioxamine: a 12-month trial. Blood Cells Mol Dis. 2006;36(1):21–25.
   PubMed Web of Science ®Google Scholar
• Galanello R, Kattamis A, Piga A, A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia. Haematologica. 2006;91(9):1241–1243.
   PubMed Web of Science ®Google Scholar
• Christoforidis A, Haritandi A, Tsatra I, Tsitourides I, Karyda S, Athanassiou-Metaxa M. Four-year evaluation of myocardial and liver iron assessed prospectively with serial MRI scans in young patients with β-thalassaemia major: comparison between different chelation regimens. Eur J Haematol. 2007;78(1):52–57.
   PubMed Web of Science ®Google Scholar
• Tanner MA, Galanello R, Dessi C, A randomized, placebo controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation. 2007;115(14):1876–1884.
   PubMed Web of Science ®Google Scholar
• Perifanis V, Christoforidis A, Vlachaki E, Tsatra I, Spanos G, Athanassiou-Metaxa M. Comparison of effects of different long-term iron-chelation regimens on myocardial and hepatic iron concentrations assessed with T2* magnetic resonance imaging in patients with β-thalassemia major. Int J Hematol. 2007;86(5):385–389.
   PubMed Web of Science ®Google Scholar
• El-Beshlawy A, Manz C, Naja M, Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience. Ann Hematol. 2008;87(7):545–550.
   PubMed Web of Science ®Google Scholar
• Tsironi M, Assimakopoulos G, Polonofi K, Rigaki K, Aessopos A. Effects of combined deferiprone and deferoxamine chelation therapy on iron load indices in β-thalassemia. Hemoglobin. 2008;32(1–2):29–34.
   PubMed Web of Science ®Google Scholar
• Kushner JP, Porter JP, Olivieri NF. Secondary iron overload. Hematology Am Soc Hematol Educ Program. 2001:47–61.
   PubMedGoogle Scholar
• Breuer W, Empers MJJ, Pootrakul P, Deferoxamine chelatable iron, a component of serum non-transfusion-bound iron, used for assessing chelation therapy. Blood. 2001;97(3):792–798.
   PubMed Web of Science ®Google Scholar
• Cohen AR, Galanello R, Pennell DJ, Cunningham MJ, Vichinsky E. Thalassemia. Hematology Am Soc Hematol Educ Program. 2004:14–34.
   PubMedGoogle Scholar
• Agarwal MB, Gupte SS, Viswanathan C, Long-term assessment of efficacy and safety of deferiprone, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial. Br J Haematol. 1992; 82(2):460–466.
   PubMed Web of Science ®Google Scholar
• Galanello R. Deferiprone in the treatment of transfusion-dependent thalassemia: a review and perspective. Ther Clin Risk Manag. 2007;3(5):795–805.
   PubMedGoogle Scholar
• Kolnagou A, Economides Ch, Eracleous E, Kontoghiorghes GJ. Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols. Hemoglobin. 2008;32(1–2):41–47.
   PubMed Web of Science ®Google Scholar
• Drakonaki EE, Maris TG, Papadakis A, Karantanas AH. Bone marrow changes in β-thalassemia major: quantitative MR imaging findings and correlation with iron stores. Eur Radiol. 2007;17(7):2079–2087.
   PubMedGoogle Scholar
• Papakonstantinou O, Drakonaki EE, Maris T, Vasiliadou A, Papadakis A, Gourtsoyiannis N. MR imaging of spleen in β-thalassemia major. Abdom Imaging. 2006:12.
   Google Scholar
• Kaltwasser JP, Gottschalk R, Schalk KP, Non-invasive quantitation of liver iron-overload by magnetic resonance imaging. Br J Haematol. 1990;74(3):360–363.
   PubMed Web of Science ®Google Scholar
• Mazza P, Giua R, De Marco S, Iron overload in thalassemia: comparative analysis of magnetic resonance imaging, serum ferritin and iron content of the liver. Haematologica. 1995;80(5):398–404.
   PubMed Web of Science ®Google Scholar
• Papakonstantinou O, Alexopoulou E, Economopoulos N, Assessment of iron distribution between liver, spleen, pancreas, bone marrow, and myocardium by means of R2 relaxometry with MRI in patients with β-thalassemia major. J Magn Reson Imaging. 2009;29(4):853–859.
   PubMed Web of Science ®Google Scholar